$3.07
▲ +$0.17
(+5.86%)
Vol 714K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$101.8M
ROE
-97.1%
Margin
-58.8%
D/E
0.00
Beta
1.51
52W
$1–$4
Wall Street Consensus
13 analysts · Apr 20263
Strong Buy
4
Buy
6
Hold
0
Sell
0
Strong Sell
53.8%
Buy Rating
Price Chart
Similar Stocks
NVCT
Nuvectis Pharma Inc
$193.4M
ANIK
Anika Therapeutics Inc
$138.6M
SABS
SAB Biotherapeutics Inc
P/E 9.5
$178.0M
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
CRBP
Corbus Pharmaceuticals Holdings Inc
$142.9M
GALT
Galectin Therapeutics Inc
$268.2M
Earnings
Beat rate: 100.0%
Next Report
May 11, 2026
EPS Estimate: $-0.54
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.54 | — | — |
| Dec 2025 | $-0.30 | $-0.23 | +$0.07 |
| Sep 2025 | $-0.50 | $0.27 | +$0.77 |
| Jun 2025 | $-0.62 | $-0.57 | +$0.05 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -39.8% | -59.8% | -40.2% | -40.2% | -98.3% | -97.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -161.9% | -36.2% | -22.0% | -22.0% | -59.5% | -58.8% |
| Gross Margin | 60.0% | 89.9% | 86.9% | 86.9% | 75.4% | 75.4% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 5.26 | 3.28 | 5.25 | 5.25 | 5.22 | 5.27 |
Key Ratios
ROA (TTM)
-29.9%
P/S (TTM)
0.80
P/B
1.8
EPS (TTM)
$-1.19
CF/Share
$0.98
Rev Growth 3Y
+24.7%
52W High
$3.60
52W Low
$0.99
$0.99
52-Week Range
$3.60
How does MGNX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
MGNX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
0.8
▼
94%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.8
▼
29%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
MGNX profitability vs Biotechnology peers
ROE
-97.1%
▼
44%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-58.8%
▲
80%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
75.4%
▼
4%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-29.9%
▲
36%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
MGNX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
5.3
▲
19%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
1.5
▲
55%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
MGNX fundamentals radar
MGNX
Peer median
Industry
MGNX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
MGNX vs peers: key metrics
Latest News
No related news yet